Home > Back to Publisher > Report Information

European Fine Chemicals Markets - Investment Analysis and Growth Opportunities

Frost & Sullivan
July 26, 2006
SKU: MC1393107

Abstract Table of Contents Related Reports

Countries covered: Europe

Research Overview

This Frost & Sullivan research service titled European Fine Chemicals Market - Investment Analysis & Growth Opportunities provides financial benchmarking analysis of the biometrics industry - ratio analysis, year-to-date performance of Frost & Sullivan biometrics stocks and valuation multiples for biometric companies. It includes a growth monitor that ranks companies based on prospective revenue growth, and industry growth outlook that discusses market estimates until 2008. In this research service, Frost & Sullivan's expert analysts thoroughly examine the following markets: pharmaceutical intermediates, active pharmaceutical ingredients, contract biopharma, agrochemical intermediates.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

Pharmaceutical intermediates
Active Pharmaceutical Ingredients
Contract Biopharma
Agrochemical intermediates

Market Overview

Upswing in Market for European Pharmaceutical Fine Chemical Companies, Consolidate for Success<

Prospects are bright for the European fine chemicals market due to the restructuring efforts of pharmaceutical companies, increased capacity utilization rates by fine chemicals manufacturers, and the market’s focus on niche areas. In recent years, the market has faced fierce competition from Asian companies, particularly Indian and Chinese. However, since 2005, the industry has overcome slow drug approval rates, overcapacity in the market, as well as pricing pressures.

Declining profits and stagnant demand have been driving fine chemical companies to consolidate to reduce competition, marketing costs, and gain better economies of scale. Moreover, to benefit from the restructuring efforts of pharmaceuticals, it is necessary for fine chemical companies to have critical mass. Hence, the market has undervalued the stocks offering attractive valuations for potential mergers and acquisitions. Increasing direct investment by Asian companies in the European market is also propelling consolidation. "Europe is seen as a launch pad into the U.S. market and this is also a positive sign for private equity participants and a good exit option as consolidation continues," states the analyst of this research service.

Look Beyond Technology, Focus on Niche Markets

In the next few years, European companies need to go beyond technology and become a service provider for the pharmaceuticals industry. The focus is likely to be on services, which involves more guidance and consulting. "Industry experts are optimistic about the future, as there is a slew of new project bookings and downsizing by the fine chemical market participants," says the analyst.

European companies can exploit the high-value niche markets where competition from Asian companies is expected to be minimal. Focus on segments such as High Potency Active Pharmaceutical Ingredients (HPAPI), hazardous chemistry, azide chemistry market, and nano particle processing could be beneficial. Currently, the contract biopharma segment is poised to grow rapidly because of a promising pipeline of biopharmaceutical drugs that may enter the market due to the increased venture capitalist involvement. Greater investment in research and development (R&D) in the mature agrochemical intermediates segment is also likely to bring about growth.

1. Executive Summary
        1. Executive Summary
                  1. Executive Summary

2. Introduction
        1. Introduction
                  1. Introduction
        2. Methodology
                  1. Methodology

3. Investment Analysis and Growth Opportunities in the Fine Chemicals Industry
        1. Industry Fundamentals
                  1. Market Fundamentals
                  2. Pharmaceutical Intermediates and Active Pharmaceutical Ingredients
                  3. Contract Biopharma
                  4. Agrochemical Intermediates
        2. Industry Economics
                  1. Pharmaceutical Intermediates and Active Pharmaceutical Ingredients
                  2. Contract Biopharma
                  3. Agrochemical Intermediates
        3. Value Chain
                  1. Pharmaceutical Intermediates and Active Pharmaceutical Ingredients
                  2. Contract Biopharma
                  3. Agrochemical Intermediates
        4. Investment Themes
                  1. Investment Themes
        5. Sector Scorecard
                  1. Sector Scorecard
        6. Growth Monitor
                  1. Frost & Sullivan Growth Monitor
        7. Company Scorecard
                  1. Company Scorecard

4. Financial Benchmarking and Valuation
        1. Frost & Sullivan European Fine Chemicals Universe
                  1. Frost & Sullivan European Fine Chemical Universe
        2. Financial Analysis
                  1. Year-over-Year Sales Growth
                  2. Research & Development to Sales
                  3. EBITDA Margin
                  4. Operating Profit Margin
                  5. Interest Coverage & Debt Equity Ratio
                  6. Operating Margin & Net Profit Margin
                  7. Capital Expenditure to Depreciation & Amortization
                  8. Return on Capital Employed & Return on Equity
        3. Fixed Cost & Pension Analysis
                  1. Fixed Cost Analysis
                  2. Pension Analysis
        4. Valuations
                  1. Historical Valuations based on Sales & Profitability
                  2. Industry Growth Outlook
                  3. Frost & Sullivan Stock Index Performance
                  4. Year to Date Performance
                  5. Private Equity and Venture Capital Activity
        5. Mergers & Acquisitions
                  1. Mergers & Acquisitions

More Europe Biopharmaceuticals Reports

Analysis of European Biosimilars Market by Frost & Sullivan
The aim of this research study is to thoroughly assess and analyse the biosimilars market, as well as market and technology trends in Europe, in ...

Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment by GBI Research
Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment Summary GBI Research, the leading business intelligence ...

Contract Manufacturing Organizations (CMO) in Eastern Europe - Inconsistent Demand and Competition from Asia Raises Concerns by GBI Research
Contract Manufacturing Organizations (CMO) in Eastern Europe - Inconsistent Demand and Competition from Asia Raises Concerns Summary GBI Research, the leading business intelligence provider, has released its ...

Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotechnology Clusters, Funding Characteristics and Regulatory Landscape by GBI Research
Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotechnology Clusters, Funding Characteristics and Regulatory Landscape Summary GBI Research, the leading business intelligence provider, has ...

H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009 by Decision Resources
Introduction: The third quarter of 2009 saw a heated debate in the United States over healthcare reform, the publication of a report on a European ...

See all reports like this >>

More Europe Reports

A Comprehensive Study Of The UK Video Conferencing Equipment Market In 2010, Rating & Valuing Each Of The 30 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Tableware Market In 2010, Rating & Valuing Each Of The 166 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Surveyors & Valuers Market In 2010, Rating & Valuing Each Of The 943 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Subsea Engineering Market In 2010, Rating & Valuing Each Of The 142 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Structural Engineering Consultancy Market In 2010, Rating & Valuing Each Of The 300 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

See all reports like this >>

European Fine Chemicals Markets - Investment Analysis and Growth Opportunities

Share this report

Other tasks

Research Assistance

Related Markets

Biopharmaceuticals Reports

Free Alert Me service